SCHEMBL6670119

SCHEMBL6670119

Cc1nc2cc(Cl)ccc2c(=O)[nH]1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYMS P04818 2/20 0.63
PARP1 P09874 3/20 0.59
TNKS2 Q9H2K2 1/20 0.59
ALDH1A1 P00352 3/20 0.58
KDM4E B2RXH2 3/20 0.58
MAPT P10636 3/20 0.58
NPC1 O15118 2/20 0.58
HPGD P15428 2/20 0.58
USP2 O75604 1/20 0.58
GLA P06280 1/20 0.58
GAA P10253 1/20 0.58
RAB9A P51151 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
TRPV1 Q8NER1 1/20 0.57
TUBB4A P04350 1/20 0.54
TUBB P07437 1/20 0.54
TUBA3C P0DPH7 1/20 0.54
TUBA1B P68363 1/20 0.54
TUBA4A P68366 1/20 0.54
TUBB4B P68371 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5313776 0.86 TYMS (0.72) TYMSPARP1TNKS2ALDH1A1KDM4E
SCHEMBL31463101 0.86 TYMS (0.72) TYMSPARP1TNKS2ALDH1A1KDM4E
SCHEMBL30704851 0.82 PARP1 (0.62) TYMSPARP1TNKS2ALDH1A1KDM4E
SCHEMBL17460813 0.82 PARP1 (0.62) TYMSPARP1TNKS2ALDH1A1KDM4E
SCHEMBL3037555 0.82 TUBB4A (0.56) TYMSPARP1TNKS2ALDH1A1KDM4E
SCHEMBL26017734 0.79 TUBB4A (0.54) TYMSPARP1TNKS2ALDH1A1KDM4E
SCHEMBL4878797 0.79 TYMS (0.63) TYMSPARP1TNKS2ALDH1A1KDM4E
SCHEMBL3226572 0.79 TYMS (0.63) TYMSPARP1TNKS2ALDH1A1KDM4E
SCHEMBL29440611 0.79 TYMS (0.63) TYMSPARP1TNKS2ALDH1A1KDM4E
SCHEMBL21524672 0.79 CNR1 (0.51) PARP1TNKS2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2935246-B1 ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD CALISTOGA LLC (US) 2018-07-25 EP disclosed
US-9951029-B2 Styryl quinazoline derivatives as pharmaceutically active agents VICHEM CHEMIE KUTATÓ KFT. (HU) 2018-04-24 US disclosed
EP-3008053-B1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD CALISTOGA LLC (US) 2018-03-21 EP disclosed
EP-3229593-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS Synereca Pharmaceuticals, Inc. (US) 2017-10-18 EP disclosed
US-20160194291-A1 STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS VICHEM CHEMIE KUTATÓ KFT. (HU) 2016-07-07 US disclosed
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS (US) 2016-06-16 US disclosed
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS (US) 2016-06-16 US disclosed
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS (US) 2016-06-16 US disclosed
WO-2016094730-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS, INC. (US) 2016-06-16 WO disclosed
WO-2016094730-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS, INC. (US) 2016-06-16 WO disclosed
WO-2014100767-A1 ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD CALISTOGA LLC (US) 2014-06-26 WO disclosed
WO-2004030671-A2 USE OF 4-AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
CN-1474816-A 4-amino-quinazolines Ĭ��ר���ɷ����޹�˾ 2004-02-11 CN disclosed
EP-1318985-A2 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024666-A2 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed
US-5610301-A Process for the regioselective n-alkylation of quinazolinones AMERICAN CYANAMID COMPANY (US) 1997-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS FOS, FOSB, YAP1 TYMS 2076/4885PARP1 2477/4885TNKS2 2811/4885
US-20160194291-A1 STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS FLT3, BCR, STK3 TYMS 231/4885PARP1 1606/4885TNKS2 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.